Figure 2.
CTA expression in recurrent and non-recurrent prostate cancer. CTA expression of (a) CEP55, (b) NUF2 and (c) PAGE4 in clinically localized prostate cancer with recurrence (Rec (+)) (n=43) and without recurrence (Rec (−)) (n=29), were examined using multiplexed quantitative real time PCR. Adapted from Ref. 39. For details of the method, see Ref. 39. CTA, cancer/testis antigen.